Central Pacific Bank Trust Division Buys 3,633 Shares of Cencora, Inc. $COR

Central Pacific Bank Trust Division boosted its position in shares of Cencora, Inc. (NYSE:COR) by 654.6% in the third quarter, Holdings Channel.com reports. The firm owned 4,188 shares of the company’s stock after acquiring an additional 3,633 shares during the period. Central Pacific Bank Trust Division’s holdings in Cencora were worth $1,309,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Cencora by 9.0% during the third quarter. GAMMA Investing LLC now owns 7,449 shares of the company’s stock worth $2,328,000 after buying an additional 618 shares in the last quarter. Park National Corp OH grew its stake in shares of Cencora by 5.3% during the 3rd quarter. Park National Corp OH now owns 36,610 shares of the company’s stock worth $11,442,000 after acquiring an additional 1,849 shares in the last quarter. Farmers Trust Co. raised its holdings in shares of Cencora by 0.8% in the third quarter. Farmers Trust Co. now owns 8,266 shares of the company’s stock valued at $2,583,000 after purchasing an additional 67 shares during the last quarter. Capital A Wealth Management LLC lifted its position in shares of Cencora by 3,975.0% in the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after purchasing an additional 159 shares in the last quarter. Finally, National Wealth Management Group LLC boosted its holdings in Cencora by 7.4% during the second quarter. National Wealth Management Group LLC now owns 1,865 shares of the company’s stock worth $559,000 after purchasing an additional 128 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

COR has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 8th. Finally, TD Cowen boosted their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $373.50.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders sold 15,290 shares of company stock valued at $5,012,227. 10.80% of the stock is owned by insiders.

Cencora Price Performance

NYSE:COR opened at $350.33 on Tuesday. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $377.54. The firm has a market cap of $67.96 billion, a price-to-earnings ratio of 44.07, a P/E/G ratio of 1.64 and a beta of 0.63. The firm’s 50-day simple moving average is $344.19 and its 200 day simple moving average is $311.91. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the previous year, the firm posted $3.34 EPS. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.